French minister calls for extension of EU-US trade talks
PARIS (Reuters) -France's finance minister has called for extending EU-U.S. trade talks beyond the July 9 deadline in order to secure a better agreement.
U.S. President Donald Trump has set the deadline for the trade talks, warning that failure to reach agreement could trigger higher U.S. tariffs on goods from cars to pharmaceuticals.
Progress in the negotiations between the huge trading partners remains unclear. European officials are increasingly resigned to a 10% "reciprocal" tariff imposed by Washington in April being the baseline in any deal, sources familiar with the talks have told Reuters.
"I think that we are going to strike a deal with the Americans," French Finance Minister Eric Lombard told newspaper La Tribune Dimanche in an interview published on Sunday.
"Regarding the deadline, my wish is for another postponement. I would rather have a good deal than a bad deal on July 9," he said.
U.S. Treasury Secretary Scott Bessent said earlier this month that deadlines on some countries negotiating in good faith could be extended.
French President Emmanuel Macron said following an EU summit on Thursday that France wants a quick and pragmatic trade deal with the United States but would not accept unbalanced terms.
EU leaders discussed a new U.S. proposal at the summit but the European Commission did not reveal the content of the offer.
Lombard said that energy could form part of a trade deal, with the EU potentially increasing its imports of U.S. gas to replace flows from Russia.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
argenx Advances Clinical Development of ARGX-119 in Congenital Myasthenic Syndromes
Phase 1b study supports proof-of-concept in DOK7 congenital myasthenic syndromes Decision informed by favorable safety profile and consistent functional improvement over time across multiple efficacy measures Advancing ARGX-119 further validates strong track record of Immunology Innovation Program (IIP), argenx's collaborative discovery model June 30, 2025, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced its plan to advance the clinical development of ARGX-119, a first-in-class agonist antibody to muscle-specific kinase (MuSK), to a registrational study in patients with congenital myasthenic syndromes (CMS) following the analysis of topline data from the Phase 1b study. Detailed results will be presented at a future medical meeting. 'The results of our Phase 1b ARGX-119 study in congenital myasthenic syndromes, an ultra-rare disorder that affects patients from birth, builds on our experience and understanding of myasthenic disorders and aligns with our aspiration to serve even more patients living with these debilitating diseases,' said Luc Truyen, M.D., Ph.D., Chief Medical Officer of argenx. 'ARGX-119 is the sixth molecule developed through our Immunology Innovation Program to show proof-of-concept, reflecting the strength of our innovation model where our deep knowledge of the biology and expertise in antibody engineering come together to push the boundaries of what's possible. argenx remains focused on uncovering new biological insights into misunderstood diseases to meaningfully change the lives of patients who have long-been underserved,' said Peter Ulrichts, Ph.D., Chief Scientific Officer of argenx. The decision to advance the development of ARGX-119 in CMS is supported by the results of the Phase 1b study. ARGX-119 demonstrated a favorable safety and tolerability profile, which was the primary endpoint. Efficacy was evaluated across multiple secondary and exploratory endpoints, including Six-Minute Walk Test (6MWT), Quantitative Myasthenia Gravis (QMG) score and Myasthenia Gravis Activities of Daily Living (MG-ADL) score. Consistent improvements were observed in treated DOK7-CMS patients through the 12-week study across multiple efficacy scores. Phase 1b CMS Study Design The Phase 1b, multicenter, randomized, double-blinded, placebo-controlled clinical trial assessed safety, tolerability, PK, immunogenicity, and preliminary efficacy of ARGX-119 in participants with DOK7-CMS. The study was also designed to demonstrate proof-of-biology through preliminary efficacy assessments, including muscle weakness, fatigability, daily activities and patient-reported global health outcomes. The clinical trial spanned approximately 11 months across a screening period (up to 28 days), a 12-week treatment period and a follow-up period of nearly seven months. At baseline, eligible participants were randomized 4:1 to receive intravenous ARGX-119 or placebo. The primary objective was to evaluate safety and tolerability; secondary objectives included PK, immunogenicity and preliminary efficacy of ARGX-119 in participants with DOK7-CMS. All but one of the patients enrolled in the Phase 1b study also participated in an observational natural history study initiated by argenx in 2024 to better understand the CMS patient journey and disease burden, helping to inform future development plans. About Congenital Myasthenic Syndromes Congenital Myasthenic Syndromes (CMS) are an ultra-rare and heterogenous group of congenital neuromuscular disorders caused by genetic defects that are essential for the integrity of the neuromuscular junction. Early age of onset and fatigable muscle weakness are considered clinical hallmarks of CMS. Muscle weakness can be debilitating and life-threatening causing difficulties in speaking or swallowing, impaired or absent mobility, proximal arm and leg weakness, and respiratory insufficiency. DOK7 variations are one of the more frequent and severe causes of CMS, accounting for approximately 24% of CMS cases. There are no approved treatments. The prevalence of CMS is estimated to be 5 per 1M (DOK7-CMS estimated to be 1.2 per 1M). About ARGX-119 ARGX-119 is a first-in-class humanized agonist monoclonal antibody (mAb) that specifically targets and activates muscle-specific tyrosine kinase (MuSK) to promote maturation and stabilization of the neuromuscular junction (NMJ). It is a mAb derived from llamas and discovered using the argenx SIMPLE Antibody™ platform technology. ARGX-119 is being developed for patients with neuromuscular disease, including congenital myasthenic syndromes (CMS), amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA). ARGX-119 was developed through argenx's IIP program in collaboration with the world's leading key opinion leaders on MuSK and the NMJ, Professor Steven J. Burden from MGH, Professor Shohei Koide from NYU and Professor Jan Verschuuren and Associate Professor Maartje Huijbers from LUMC. About argenx argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit and follow us on LinkedIn, Instagram, Facebook, and YouTube. Media: Colin McBeancmcbean@ Investors: Alexandra Roy aroy@ Forward Looking Statements The contents of this announcement include statements that are, or may be deemed to be, 'forward looking statements.' These forward-looking statements can be identified by the use of forward-looking terminology, including the terms 'aims,' 'committed,' or 'plan' and include statements argenx makes concerning its commitment to improving the lives of people suffering from severe autoimmune diseases; its plan to advance the clinical development of ARGX-119 to a registrational study in CMS patients; and its goal of translating immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. argenx's actual results may differ materially from those predicted by the forward-looking statements as a result of various important factors, including but not limited to, the results of argenx's clinical trials; expectations regarding the inherent uncertainties associated with the development of novel drug therapies; preclinical and clinical trial and product development activities and regulatory approval requirements; the acceptance of its products and product candidates by its patients as safe, effective and cost-effective; the impact of governmental laws and regulations, including tariffs, export controls, sanctions and other regulations on its business; its reliance on third-party suppliers, service providers and manufacturers; inflation and deflation and the corresponding fluctuations in interest rates; and regional instability and conflicts. A further list and description of these risks, uncertainties and other risks can be found in argenx's U.S. Securities and Exchange Commission (SEC) filings and reports, including in argenx's most recent annual report on Form 20-F filed with the SEC as well as subsequent filings and reports filed by argenx with the SEC. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. argenx undertakes no obligation to publicly update or revise the information in this press release, including any forward-looking statements, except as may be required by in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
'Insane': Trump's Baffling New Comments On Japan Leave Critics Aghast
President Donald Trump suggested new tariffs on Japan ― but then spaced on the name of the nation's leader. Trump told Fox News host Maria Bartiromo he would be sending out letters as his pause on tariffs ends early next month, and cited Japan as an example. Rather than name Japanese Prime Minister Shigeru Ishiba ― who he met in February at the White House ― Trump appeared to improvise as he described the letter. 'Dear Mr. Japan: Here's the story,' Trump said. 'You're going to pay a 25% tariff on your cars.' He said it's 'not fair' that the United States takes 'millions and millions' of Japanese cars, while Japan takes comparatively few cars from U.S. automakers. 'They won't take our cars,' Trump said, and suggested that Japan could fix that deficit with other purchases from the United States, such as oil. Trump has said in the past that his tariffs are a way to get companies, including overseas companies, to increase production in the United States. 'My message to every business in the world is very simple: Come make your product in America, and we will give you among the lowest taxes of any nation on Earth,' Trump said in January. However, the vast majority of Japanese cars sold in the United States are already built in the United States, making them less likely to be impacted by the threat of new tariffs. But it was the opening of his hypothetical letter to Japanese leaders ― the 'Dear Mr. Japan' ― that got his critics fired up on X: Dear Mr Japan? Trump doesn't know what or who he is talking about — Barbara Comstock (@BarbaraComstock) June 29, 2025 If President Biden started a sentence with "Dear Mr. Japan," Republicans would never shut up about it and "25th Amendment" is all they'd be talking is fucking INSANE. — BrooklynDad_Defiant!☮️ (@mmpadellan) June 29, 2025 Imagine if Joe Biden forgot the name of the Japanese prime minister and called him Mr Japan. I'm sure everyone would be really normal about it. — Centrism Fan Acct 🔹 (@Wilson__Valdez) June 29, 2025 Fact: Japan manufactures more cars in US than it imports to US. Japan has some $700 billion invested in US, employs close to 1 million is strength. — Robert Manning (@Rmanning4) June 29, 2025 BREAKING: Trump has no clue who the Prime Minister of Japan is so he calls him 'Mr. Japan' in the interview. How can you negotiate with somebody if you don't know their name? — Trump Lie Tracker (Commentary) (@MAGALieTracker) June 29, 2025 The same conversation in which he said, "I'm going to send letters, that's the end of the trade deal. I could send one to Japan. Dear Mr. Japan..." His brain is peanut butter. — Leslie Jones (@Spiker715) June 29, 2025 "Dear Mr. Japan"Is Jake Tapper in the house? — Bo Gardiner (@BoGardiner1) June 29, 2025 Dear Mr. Japan? — Wu Tang is for the Children (@WUTangKids) June 29, 2025 For the millionth time:(1) "We" don't give Japan cars - private companies make and endeavor to sell them. And private Japanese individuals, not "Japan," have been decling to buy them.(2) Japan pays US tariffs with the money given by American citizens when they buy those cars. — Michael Hausam (@MPHaus) June 29, 2025 Dear Mr. Japan, while hilarious, is like what in the fuck? — Jason Diamond (@jasondiamond) June 29, 2025 this dude really said 'dear mr japan' — sane (@sanelofi) June 30, 2025 Who tf is Mr. Japan — Jen Monroe (@thatjenmonroe) June 29, 2025 Domo arrigato mr. Roboto — Mark Stephen Levy ✍️ (@TheRealMarkLevy) June 29, 2025 Dear Mr Japan, here's the he wasn't the leader of the free world and, as such wasn't embarrassing our entire country, this shit would be hilarious — MothGrrrrl 🩷💛💙🏳️🌈 (@Be_la74071) June 29, 2025
Bloomberg
an hour ago
- Bloomberg
Norway Pension Fund Blacklists Firms Supplying Israeli Military
Norway's largest private pension fund has excluded two defense companies from its portfolio, citing their ties to the Israeli military and the war in Gaza. KLP Pension, which oversees about $114 billion, said in a statement on Monday that it won't invest in Oshkosh Corp. or ThyssenKrupp AG because they sell weapons to the Israeli military.
